Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 667-675 , July 2006

Radiochemical synthesis and tissue distribution of p-[18F]DMPPF, a new 5-HT1A ligand for PET, in rats

Received 3 March 2006 ,Revised 16 March 2006 ,Accepted 31 March 2006.

References 

  1. Kung HF, Stevenson DA, Zhuang Z-P, Kung M-P, Frederick D, Hurt SD. New 5-HT1A receptor antagonist: p-[3H]MPPF. Synapse. 1996;23:344–346
  2. Plenevaux A, Weissmann D, Aerts J, Lemaire C, Brihaye C, Degueldre C, et al. Tissue distribution, autoradiography and metabolism of 4-(2′-methoxyphenyl)-1-[N-(2″-pyridinyl)-p-[18F]fluorobenzamido]ethyl]piperazine (p-[18F]MPPF), a new serotonin 5-HT1A antagonist for positron emission tomography: an in vivo study in rats. J Neurochem. 2000;75:803–811
  3. Zhuang Z-P, Kung M-P, Kung HF. Synthesis and evaluation of 4-(2′-methoxyphenyl)-1-[2′-[N-(2″-pyridinyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J Med Chem. 1994;37:1406–1407
  4. Van Wijngaarden I, Tulp M, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990;188:301–312
  5. Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol J-F. Effect of endogenous serotonin on the binding of the 5-HT1A PET ligand [18F]MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis. J Neurochem. 2002;80:278–286
  6. Zimmer L, Rbah L, Giacomelli F, Le Bars D, Renaud B. A reduced extracellular serotonin level increases the 5-HT1A PET ligand [18F]MPPF binding in the rat hippocampus. J Nucl Med. 2003;44:1495–1501
  7. Passchier J, Van Waarde A, Pieterman RM, Elsinga PH, Hendrikse HN, Pruim J, et al. Delineation of serotonin 5-HT1A receptors in human brain with [18F]MPPF. J Nucl Med. 1999;40:29P
  8. Plenevaux A, Lemaire C, Salmon E, Laureys S, Fuchs S, Maquet P, et al. 5-HT1A receptors visualization with p-[18F]MPPF in healthy volunteers. J Label Compd Radiopharm. 1999;42:S60–S62
  9. Passchier J, Van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN, et al. In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. J Nucl Med. 2000;41:1830–1835
  10. Passchier J, Van Waarde A, Vaalburg W, Willemsen AT. On the quantification of [18F]MPPF binding to 5-HT1A receptors in human brain. J Nucl Med. 2001;42:1025–1031
  11. Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, et al. Modelling [18F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab. 2002;22:753–765
  12. Sanabria-Bohorquez SM, Biver F, Damhaut P, Wikler D, Veraart C, Goldman S. Quantification of 5-HT1A receptors in human brain using p-MPPF kinetic modelling and PET. Eur J Nucl Med Mol Imaging. 2002;29:76–81
  13. Merlet I, Ostrowsky K, Costes N, Ryvlin P, Isnard J, Faillenot I, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain. 2004;127:900–913
  14. Praschak-Reider N, Hussey D, Wilson AA, Carella A, Lee M, Dunn E, et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [18F]MPPF positron emission tomography study. Biol Psychiatry. 2004;56:587–591
  15. Mathis C, Simpson N, Mahmood K, Kinahan P, Mintun M. [11C]WAY100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. Life Sci. 1994;55:403–407
  16. Pike VW, Halldin C, McCarron JA, Lundkvist C, Hirani E, Olsson H, et al. [carbonyl-11C]Desmethyl-WAY100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging. 1998;25:338–346
  17. Andrée B, Halldin C, Pike VW, Gunn RN, Olsson H, Farde L. The PET radioligand [carbonyl-11C]desmethyl-WAY100635 binds to 5-HT1A receptors and provides a higher radioactive signal than [carbonyl-11C]WAY100635 in the human brain. J Nucl Med. 2002;43:292–303
  18. Crouzel C, Clark JC, Brihaye C, Langström B, Lemaire C, Meyer GJ, et al. Radiochemistry automation for PET. In:  Stöcklin G,  Pike VW editor. Radiopharmaceuticals for positron emission tomography. Methodological aspects. Dordrecht: Kluwer Academic Publishers; 1993;p. 45–79
  19. Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, et al. High yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol. 1998;25:343–350
  20. Corey E, Gras J-L, Ulrich P. A new general method for protection of the hydroxyl function. Tetrahedron Lett. 1976;17:809–812
  21. Lemaire C, Damhaut P, Lauricella B, Mosdzianowski C, Morelle J-L, Monclus M, et al. Fast [18F]FDG synthesis by alkaline hydrolysis on a low polarity phase support. J Label Compd Radiopharm. 2002;45:435–447
  22. Lemaire C, Gillet S, Guillouet S, Plenevaux A, Aerts J, Luxen A. Highly enantioselective synthesis of no-carrier-added 6-[18F]fluoro-L-dopa by chiral phase-transfer alkylation. Eur J Org Chem. 2004;2899–2904
  23. MacLean MR, Clayton RA, Templeton AG, Morecroft I. Evidence for 5-HT1-like-receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol. 1996;119:277–282
  24. Cattaneo MG, Fesce R, Vicentini LM. Mitogenic effect of serotonin in human cell lung carcinoma cells via both 5-HT1A and 5-HT1D receptors. Eur J Pharmacol. 1995;291:209–211
  25. Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, el Mestikawy S, et al. Immunocytochemical localization of serotonin 1A receptors in the rat central nervous system. J Comp Neurol. 1996;365:289–305
  26. Hamon M, Lanfumey L, el Mestikawy S, Boni C, Miquel MC, Bolanos F, et al. The main features of central 5-HT1 receptors. Neuropsychopharmacology. 1990;3:349–360
  27. Khawaja X. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res. 1995;673:217–225
  28. Vergé D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, et al. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci. 1986;6:3474–3482
  29. Dishino D, Welch M, Kilbourn M, Raichle M. Relationship between lipophilicity and brain extraction of 11C-labeled radiopharmaceuticals. J Nucl Med. 1983;1030–1038
  30. Eckelman W. Sensitivity of new radiopharmaceuticals. Nucl Med Biol. 1998;25:169–173
  31. Habgood M, Begley D, Abbott N. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol. 2000;20:231–253
  32. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev. 1999;36:179–194
  33. Naito M, Tsuruo T. Role of P-glycoprotein in the blood–brain barrier. In:  Gupta S,  Tsuruo T editor. Multidrug resistance in cancer cells. Chichester: John Willey and Sons; 1996;p. 321–333
  34. Tsuji A, Tamai I. Blood–brain barrier function of P-glycoprotein. Adv Drug Deliv Rev. 1997;25:287–298
  35. Plenevaux A, Lacan G, Defraiteur C, Gillet S, Way B, Rubins D, et al. Influence of P-glycoprotein on the tissue distribution in rats of the 5-HT1A antagonist p-[18F]MPPF. In: Society for Neuroscience 32nd annual meeting. Orlando FL. 2002;
  36. Passchier J, Van Waarde A, Doze P, Elsinga PH, Vaalburg W. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol. 2000;407:273–280

PII: S0969-8051(06)00066-7

doi: 10.1016/j.nucmedbio.2006.03.010

Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 667-675 , July 2006

Article Tools

* Image Usage & Resolution